Drugs that contain Atogepant
1. List of Qulipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
NCE-1 date: September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic